Published in Telemedicine Law Weekly, August 12th, 2006
Study 1: Breast cancer post-treatment delay of 7 days is necessary for the accurate assessment of residual tumor presence by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
"The assessment of the effectiveness of MRI-guided focused ultrasound surgery (MRIgFUS) of breast carcinomas can be performed by DCE-MRI parameters which monitor the presence of residual tumour. The aim of this study was to evaluate the effect of the post-treatment delay on this assessment," scientists in Canada reported.
"DCE-MRI data were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.